WeightWatchers emerges from bankruptcy after slimming down debts
The group filed for bankruptcy in the US in May in order to eliminate 1.15 billion US dollars (£840 million) worth of debt on its balance sheet.
The court process enabled it to restructure its finances and write off the debts, which made up more than 70% of the total amount, while agreeing new terms to pay back its lenders.
WeightWatchers' chief executive Tara Comonte had said it needed to transform amid a 'rapidly evolving weight managing landscape'.
Competition has grown fiercely with demand for prescription weight-loss injections under brand names like Mounjaro and Wegovy growing, while studies into the long-term effects of the jabs are ongoing.
On Tuesday, the group said it had appointed a new chief medical officer, physician Dr Kim Boyd, to lead the integration of emerging science into its wider lifestyle-based offering for members.
Dr Boyd said she planned to expand the company's 'legacy' by 'combining the best tools of modern medicine, like GLP-1s, with science-backed lifestyle change and the power of community to deliver better outcomes'.
GLP-1s, the scientific term for weight-loss jabs, work by reducing food cravings.
WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app.
Ms Comonte said it was a 'pivotal moment for the group, adding: 'With renewed financial strength, an expanded leadership team, and the addition of Dr Kim Boyd to lead clinical strategy and programme innovation, we're accelerating our transformation.
'In a landscape dominated by noise, quick fixes, and conflicting advice, WeightWatchers continues to lead as the most trusted, science-backed platform, proven to drive better results and lasting impact.'
The restructuring resulted in the company appointing a new board of directors.
It also revealed it would be launching a new programme later this year to support women through perimenopause, menopause, and postmenopause, through tailored nutritional and behavioural strategies.
The move will help it address a broader gap in healthcare and meet the evolving needs of millions of its members around the world, it said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
3 hours ago
- Daily Mirror
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.
Sky News
6 hours ago
- Sky News
Mounjaro manufacturer to hike UK price of weight loss drug by up to 170%
The UK cost of weight loss drug Mounjaro will increase by up to 170%, its US manufacturer has said, as the White House pushes for a price hike abroad so costs can be cut for Americans. The new price, announced by manufacturer Eli Lilly on Thursday, also applies to Lilly's type 2 diabetes medicine that has the same name. The price for a month's supply of the highest dose of the medicine will increase from £122 to £330, Lilly said, adding the adjustment will be made next month. The higher price will not affect those prescribed the medicine through the NHS, which has a separate deal, a Lilly spokesperson said. The US drugmaker said that when it launched Mounjaro in the UK it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through the NHS. "We are now aligning the list price more consistently," Lilly said. Lilly did not say what price it has agreed with the NHS, but said it was working with private UK healthcare providers who can set their own prices, such as online pharmacies, to ensure the medicines remain available. It follows Sky News earlier this month revealing only eight of 42 NHS Integrated Care Boards in England were providing the weight loss treatment to patients, and many of the rest were unable to guarantee when it would be available. 2:32 Lilly's decision comes as US President Donald Trump is pushing for lower domestic prices while encouraging price hikes overseas. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Mr Trump says he wants to narrow this gap to stop Americans from being "ripped off". The company issued a statement online saying: "Lilly supports the administration's goal of keeping the United States the world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries. "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US."
The Guardian
8 hours ago
- The Guardian
Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands
The price of the weight loss jab Mounjaro will rise by up to 170% in the UK, its US manufacturer has said, as Donald Trump ramps up pressure on drugmakers to increase their prices for Europeans so that they can make them more affordable for Americans. Eli Lilly has said it will increase the price of the drug from September, with a month's supply of the highest dose rising from £122 to £330. Mounjaro contains tirzepatide and is self-administered in once-a-week injections. When it launched in Britain in February 2024, Eli Lilly agreed to a list price 'significantly below' its other European markets to stop delays in availability of the medicine through the NHS. The increase in the list price will align it 'more consistently', the company said, although it added the NHS would not pay the new higher price to ensure continued access for the people with obesity and type 2 diabetes receiving it through the health service. Eli Lilly said it was working with private healthcare providers, which could negotiate their own confidential discounts with the company. Trump has threatened to use 'every tool in our arsenal' to crack down on pharmaceutical companies charging higher prices in the US compared with other nations. The US pays about three times more for drugs compared with other developed countries, according to the Rand Corporation thinktank. On 31 July, Trump sent letters to 17 of the world's biggest drugmakers, including Eli Lilly and Novo Nordisk, demanding cuts to drug prices for Americans within 60 days. 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government and American patients,' Trump wrote. 'But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices. 'Americans are demanding lower drug prices, and they need them today.' In May, Trump told reporters that a friend in London had told him he had bought the 'fat shot drug' for $88, compared with $1,300 in New York. Pharmaceutical companies have cashed in on huge demand for weight loss treatments. Denmark's Novo Nordisk has become one of the most prominent names in the field, launching Wegovy in the UK in September 2023, turning it into one of the most valuable companies in Europe. While the jabs have increased profits at big pharmaceutical companies, they are racing to develop an equivalent pill, which would be a more convenient and cheaper alternative for patients and healthcare authorities. Eli Lilly said this month that a pill in early trial stages showed that participants on their highest dose lost an average of 12.4% of their body weight, compared with 0.9% of the control group. Novo Nordisk has submitted its oral weight loss drug for approval in the US. Its trial results showed that participants could lose about 15% of their body weight.
